Hila Magen

Dr. Hila Magen directs the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is an expert in plasma cell disorders and advanced cellular therapies. The specialist is a principal investigator for point-of-care CAR-T cell programs.

Specialization in Plasma Cell Disorders

Dr. Magen treats relapsed and refractory multiple myeloma. She treats amyloidosis and various plasma cell malignancies using precision medicine. The specialist integrates new immunotherapies into routine clinical care for high-risk patients. Her approach involves creating targeted treatment plans to improve long-term survival.

Advanced Cellular Therapies and Procedures

The doctor applies CAR-T cell therapy for blood cancers. She offers patients early access to treatments through international clinical trials. Dr. Magen performs or oversees several critical hematologic procedures:

• CAR T-cell therapy — a treatment that uses genetically modified immune cells to attack cancer
• Bone marrow transplantation from related and unrelated donors
• Haploidentical stem cell transplantation
• Therapeutic apheresis and plasmapheresis — procedures that filter and clean a patient's blood
• Diagnostic bone marrow biopsy and immunohistochemistry

Work Experience and Leadership

• Head of the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center
• Instructor at Tel Aviv University
• Principal Investigator for point-of-care CAR-T cell research studies
• Active reviewer for several international medical journals

Education and International Training

• Fellowship in Multiple Myeloma – University of Arkansas for Medical Sciences (UAMS)
• Fellowship in Lymphocytic Leukemia – MD Anderson Cancer Center, USA
• MD Degree in General Medicine

Research and Academic Achievements

Dr. Magen has authored over 100 scientific publications in peer-reviewed journals. She has contributed to multiple landmark studies regarding myeloma treatment protocols. The doctor frequently presents her clinical findings at international hematology conferences. She focuses her research on developing next-generation cellular therapies for refractory diseases.

Professional Memberships

The doctor is a member of several professional organizations:

• European Hematology Association (EHA)
• American Society of Hematology (ASH)
• Israel Society of Hematology and Blood Transfusion